Nicholas L Zalewski1, Vanda A Lennon1,2,3, Daniel H Lachance1,2, Christopher J Klein1,2, Sean J Pittock1,2, Andrew Mckeon1,2. 1. Department of Neurology, College of Medicine, Mayo Clinic, Rochester, Minnesota, USA. 2. Department of Laboratory Medicine and Pathology, College of Medicine, Mayo Clinic, Rochester, Minnesota, USA. 3. Department of Immunology, College of Medicine, Mayo Clinic, 200 First Street SW, Rochester, Minnesota, 55905, USA.
Abstract
INTRODUCTION: Voltage-gated calcium-channel autoimmunity (VGCC-P/Q and VGCC-N types) occurs beyond Lambert-Eaton syndrome and lung cancer. METHODS: We reviewed records for 236 Mayo Clinic patients with VGCC antibodies found in evaluation for paraneoplastic neurological autoimmunity (generally without myasthenic syndromes). RESULTS: VGCC autoantibodies were detected in 3.4% of neurological patients, 1.7% of healthy controls, and 4% of neurologically asymptomatic lung cancer controls. Fifty neurological patients (21%) had ≥ 1 neoplasm, historically (46) or detected prospectively [small-cell lung carcinoma (2), breast adenocarcinoma (2), lymphoma (1), and suspected tonsillar carcinoma (1)]. Autoimmune neurological diagnosis frequencies (encephalopathy, ataxia, myelopathy, neuropathy, neuromuscular junction disorder, and myopathy) among patients with medium values (24%; 0.10-0.99 nmol/L) or low values (19%; 0.03-0.10 nmol/L) were fewer than among patients with antibody values exceeding 1.00 nmol/L (71%; P = 0.02 and 0.004, respectively). CONCLUSIONS: Among neuronal VGCC-autoantibody-seropositive patients, autoimmune neurological phenotypes and cancer types are diverse. Cautious interpretation of results (particularly medium and low values) is advised. Muscle Nerve, 2016 Muscle Nerve 54: 220-227, 2016.
INTRODUCTION: Voltage-gated calcium-channel autoimmunity (VGCC-P/Q and VGCC-N types) occurs beyond Lambert-Eaton syndrome and lung cancer. METHODS: We reviewed records for 236 Mayo Clinic patients with VGCC antibodies found in evaluation for paraneoplastic neurological autoimmunity (generally without myasthenic syndromes). RESULTS: VGCC autoantibodies were detected in 3.4% of neurological patients, 1.7% of healthy controls, and 4% of neurologically asymptomatic lung cancer controls. Fifty neurological patients (21%) had ≥ 1 neoplasm, historically (46) or detected prospectively [small-cell lung carcinoma (2), breast adenocarcinoma (2), lymphoma (1), and suspected tonsillar carcinoma (1)]. Autoimmune neurological diagnosis frequencies (encephalopathy, ataxia, myelopathy, neuropathy, neuromuscular junction disorder, and myopathy) among patients with medium values (24%; 0.10-0.99 nmol/L) or low values (19%; 0.03-0.10 nmol/L) were fewer than among patients with antibody values exceeding 1.00 nmol/L (71%; P = 0.02 and 0.004, respectively). CONCLUSIONS: Among neuronal VGCC-autoantibody-seropositive patients, autoimmune neurological phenotypes and cancer types are diverse. Cautious interpretation of results (particularly medium and low values) is advised. Muscle Nerve, 2016 Muscle Nerve 54: 220-227, 2016.
Authors: Orna O'Toole; Vanda A Lennon; J Eric Ahlskog; Joseph Y Matsumoto; Sean J Pittock; James Bower; Robert Fealey; Daniel H Lachance; Andrew McKeon Journal: Neurology Date: 2013-02-20 Impact factor: 9.910
Authors: V A Lennon; T J Kryzer; G E Griesmann; P E O'Suilleabhain; A J Windebank; A Woppmann; G P Miljanich; E H Lambert Journal: N Engl J Med Date: 1995-06-01 Impact factor: 91.245
Authors: Andrew McKeon; Vanda A Lennon; Daniel H LaChance; Christopher J Klein; Sean J Pittock Journal: Muscle Nerve Date: 2013-03-05 Impact factor: 3.217
Authors: Erika S Horta; Vanda A Lennon; Daniel H Lachance; Sarah M Jenkins; Carin Y Smith; Andrew McKeon; Christopher Klein; Sean J Pittock Journal: Clin Cancer Res Date: 2014-05-15 Impact factor: 12.531
Authors: Jeremy K Cutsforth-Gregory; Andrew McKeon; Elizabeth A Coon; David M Sletten; Mariana Suarez; Paola Sandroni; Wolfgang Singer; Eduardo E Benarroch; Robert D Fealey; Phillip A Low Journal: Mayo Clin Proc Date: 2018-08-28 Impact factor: 7.616
Authors: Matthew J Ebright; Shih-Hon Li; Evan Reynolds; James F Burke; Ben R Claytor; Anna Grisold; Mousumi Banerjee; Brian C Callaghan Journal: Neurology Date: 2018-10-26 Impact factor: 9.910